Home > Insider Trading > Filing (0001209191-22-003192)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1868734	Cincor Pharma Inc.	CINC	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1245624	James Healy	C/O Cincor Pharma, Inc 200 Clarendon Street, 6Th Floor Boston MA 02116		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-01-11	5,248,949	$0.00	5,248,949	No	4	C	Indirect	By Sofinnova Venture Partners X, L.P.
Common Stock	Acquisiton	2022-01-11	325,000	$16.00	5,573,949	No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Sofinnova Venture Partners X, L.P.
No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2022-01-11	13,571,428	$0.00	3,991,596	$0.00
Common Stock	Series B Preferred Stock	Disposition	2022-01-11	4,275,000	$0.00	1,257,353	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.
The shares are directly held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. The Reporting Person is a managing member of SM X and may be deemed to share voting and dispositive power over the shares held by SVP X. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.